More recently, immunotherapy aimed at altering immune checkpoint inhibition through the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and mostly through programmed cell death protein (PD1/PD-L1) pathways [7,8,9,10] has become the standard of care for patients with NSCLC who do not have driver gene mutations. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.